TOP TEN perturbations for 38906_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38906_at
Selected probe(set): 206937_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38906_at (206937_at) across 6674 perturbations tested by GENEVESTIGATOR:

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):-4.3788595
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

AML study 1 (t(15;17)(q22;q11-12)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.467783
Number of Samples:36 / 74
Experimental AML study 1 (t(15;17)(q22;q11-12))
Bone marrow samples of patients with acute promyelocytic leukemia [subtype of acute myeloid leukemia (AML)] with genetic aberration (t(15;17)(q22;q11-12)/PML-RARα and variations).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

AML study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.3570385
Number of Samples:38 / 74
Experimental AML study 1 (t(11q23))
Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

mature B-ALL study 1 (t(8;14)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.1910105
Number of Samples:13 / 74
Experimental mature B-ALL study 1 (t(8;14))
Bone marrow samples of patients with mature B-ALL (t(8;14)).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

AML study 1 (t(8;21)(q22;q22)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.1215506
Number of Samples:40 / 74
Experimental AML study 1 (t(8;21)(q22;q22))
Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (t(8;21)(q22;q22)).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 3 (TEL-AML1) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):3.0206003
Number of Samples:15 / 5
Experimental precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.0191107
Number of Samples:70 / 74
Experimental precursor-B-ALL study 1 (t(11q23))
Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

sickle cell disease study 2 (Globin red.) / normal blood sample

Relative Expression (log2-ratio):2.9014797
Number of Samples:5 / 5
Experimental sickle cell disease study 2 (Globin red.)
Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene™ Blood RNA System Kit followed by an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclear™-Human kit.
Control normal blood sample
Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit including an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclearTM-Human kit.

T-ALL study 1 / normal bone marrow sample

Relative Expression (log2-ratio):-2.856701
Number of Samples:174 / 74
Experimental T-ALL study 1
Bone marrow samples of patients with T-ALL.
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

AML study 1 (inv(16)/t(16;16)) / normal bone marrow sample

Relative Expression (log2-ratio):-2.8332577
Number of Samples:28 / 74
Experimental AML study 1 (inv(16)/t(16;16))
Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (inv(16)/t(16;16)).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.